Core Viewpoint - The establishment of the Lecheng Branch of the Hainan Drug and Medical Device Review Service Center aims to enhance the pharmaceutical and medical device regulatory environment in Hainan Free Trade Port and accelerate the transformation of medical innovation in the Boao Lecheng International Medical Tourism Pilot Zone [1] Group 1: Establishment and Purpose - The Lecheng Branch is a collaborative initiative by the Hainan Provincial Drug Administration, Qionghai Municipal Government, and the Lecheng Pilot Zone Management Bureau to adapt to new operational conditions and innovate drug and medical device management concepts and service models [1] - The center will serve as a professional, one-stop service platform that integrates policy facilitation, technical guidance, and expedited approvals, acting as both a "gatekeeper" and a "service provider" [1] Group 2: Future Plans and Development - The Hainan Provincial Drug Administration plans to work with relevant departments to use the establishment of the Lecheng Branch as a starting point to implement measures supporting the high-quality development of the biopharmaceutical industry [1] - There will be a focus on enhancing regulatory capacity and professional talent training, as well as exploring regulatory service mechanisms that align with international standards [1] - The goal is to create a model for drug and medical device review services that reflects Hainan's characteristics and Lecheng's advantages, thereby supporting the high-standard construction of Hainan Free Trade Port [1]

Core Viewpoint - The establishment of the Beijing-Tianjin-Hebei (Jing-Jin-Ji) Center for Drug and Medical Device Review and Inspection is a significant step by the National Medical Products Administration (NMPA) to enhance the drug and medical device approval system, promote innovation, and support high-quality development of the regional pharmaceutical industry [1][2] Group 1: Center Functions and Responsibilities - The Jing-Jin-Ji Center will serve the regions of Beijing, Tianjin, Hebei, and Shandong, providing technical services related to drug and medical device review, including research guidance, consultation acceptance, and review communication [1] - The center will also undertake registration verification and conduct inspections, contributing to the overall efficiency and quality of the review process [2] Group 2: Regional Pharmaceutical Industry Impact - Since 2021, the Jing-Jin-Ji region has approved 34 innovative drugs, accounting for 16.2% of the national total, and 68 Class III innovative medical devices, representing 25.7% of the national total [1] - The pharmaceutical industry's revenue in the region is projected to reach 841.5 billion yuan in 2024, which will constitute 28.3% of the national revenue [1]